A new study of the longest-acting form of injectable PrEP, lenacapavir, has shown no adverse interactions with hormone therapy for trans women and men. Marketed under the brand name Yeztugo by Gilead ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

Dominick Dunlap began taking female hormones at age 26 after just one visit to a gender clinic to have a “more feminine appearance.” Less than two years later, he was dead. Despite having a family ...

The addition of the hormone progesterone to gender-affirming hormone therapy leads to increased breast growth for transgender people following feminizing hormone therapy. This is demonstrated by an ...

Gender-affirming hormone therapy does more than reshape the body; it shifts the heart’s electrical rhythm, too, helping it align with a person’s gender identity, according to new research into cardiac ...

Lenacapavir does not appear to cause any clinically significant effects in the pharmacokinetics of long-acting hormonal contraceptives or gender-affirming hormone therapy, according to a pair of ...